Patents by Inventor Yasmin Thanavala
Yasmin Thanavala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10738119Abstract: Provided are methods and compositions for a combination therapy for liver disorders such as hepatocellular carcinoma. Also provided is a method for determining the effectiveness of therapy involving tyrosine kinase inhibitors such as sorafenib. The method comprises determining the status of PD-1 on T cells, and based on a change in the level of PD-1 on certain cells, a determination of the effectiveness of the tyrosine kinase, and an indication for a combination therapy comprising a lower dose of tyrosine kinase inhibitor and a PD-1 inhibitor can be made.Type: GrantFiled: February 18, 2015Date of Patent: August 11, 2020Assignee: Health Research, Inc.Inventor: Yasmin Thanavala
-
Publication number: 20180162941Abstract: Provided are methods and compositions for a combination therapy for liver disorders such as hepatocellular carcinoma. Also provided is a method for determining the effectiveness of therapy involving tyrosine kinase inhibitors such as sorafenib. The method comprises determining the status of PD-1 on T cells, and based on a change in the level of PD-1 on certain cells, a determination of the effectiveness of the tyrosine kinase, and an indication for a combination therapy comprising a lower dose of tyrosine kinase inhibitor and a PD-1 inhibitor can be made.Type: ApplicationFiled: February 18, 2015Publication date: June 14, 2018Inventor: Yasmin THANAVALA
-
Patent number: 7585522Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to the NEPA may be boosted in the animal by feeding the animal the plant material containing the NEPA. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g.Type: GrantFiled: December 16, 1999Date of Patent: September 8, 2009Assignee: Health Research, Inc.Inventor: Yasmin Thanavala
-
Patent number: 7572466Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by administering the plant material containing the NEPA in conjunction with a suitable adjuvant. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g. HBsAg in the plant results from expression by the plant of the NEPA due to genetic alteration.Type: GrantFiled: December 16, 1999Date of Patent: August 11, 2009Assignees: Health Research, Inc., Boyce Thompson Institute for Plant Research, Inc.Inventors: Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
-
Patent number: 7527810Abstract: A method for obtaining an immune response to hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the HBsAg. It has now been discovered that the animal may be made immunoreceptive to HBsAg either by administering the plant material containing HBsAg in conjunction with a suitable adjuvant or by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to HBsAg may be boosted in the animal by feeding the animal the plant material containing the HBsAg. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing hepatitis B surface antigen (HBsAg).Type: GrantFiled: October 19, 1999Date of Patent: May 5, 2009Assignees: Health Research, Inc., Boyce Thompson Institute for Plant Research, IncInventors: Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
-
Publication number: 20040086530Abstract: Plant expression vectors comprising at least two expression cassettes are provided which function to reduce transcriptional silencing of polynucleotide expression. Further, novel plant expression vectors for expression of immunogenic polypeptides, including HBsAg, are provided. The plant expression vectors can be used to produce immunogenic polypeptides, including HBsAg, in edible plant tissues. The edible plant tissues can be used to elicit an immune response in humans and animals when the plant tissues are consumed.Type: ApplicationFiled: January 2, 2003Publication date: May 6, 2004Applicant: Boyce Thompson InstituteInventors: Hugh S. Mason, Yasmin Thanavala, Charles Joel Arntzen, Lizabeth Ritcher
-
Patent number: 6551820Abstract: Plant expression vectors comprising at least two expression cassettes are provided which function to reduce transcriptional silencing of polynucleotide expression. Further, novel plant expression vectors for expression of immunogenic polypeptides, including HBsAg, are provided. The plant expression vectors can be used to produce immunogenic polypeptides, including HBsAg, in edible plant tissues. The edible plant tissues can be used to elicit an immune response in humans and animals when the plant tissues are consumed.Type: GrantFiled: December 23, 1999Date of Patent: April 22, 2003Assignee: Boyce Thompson Institute for Plant ResearchInventors: Hugh S. Mason, Yasmin Thanavala, Charles Joel Arntzen, Elizabeth Richter
-
Patent number: 6537265Abstract: A method for nasal application of a medicinal substance by applying the substance through the nose in a maximum amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages. Within a time period of less than one hour, the application of the substance through the nose in an amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages is repeated. The repeated application, at a minimum, is done a sufficient number of times to provide an effective total dose of the substance. The repeated application, in any case, is done at least once.Type: GrantFiled: November 5, 2001Date of Patent: March 25, 2003Assignee: Health Research, Inc.Inventors: Yasmin Thanavala, Anju Visweswaraiah, Lauren O. Bakaletz, Laura Anne Novotny
-
Publication number: 20030009149Abstract: A method for nasal application of a medicinal substance by applying the substance through the nose in a maximum amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages. Within a time period of less than one hour, the application of the substance through the nose in an amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages is repeated. The repeated application, at a minimum, is done a sufficient number of times to provide an effective total dose of the substance. The repeated application, in any case, is done at least once.Type: ApplicationFiled: June 8, 2001Publication date: January 9, 2003Inventors: Yasmin Thanavala, Anju Visweswaraiah, Lauren O. Bakaletz, Laura Anne Novotny
-
Publication number: 20020198510Abstract: A method for nasal application of a medicinal substance by applying the substance through the nose in a maximum amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages. Within a time period of less than one hour, the application of the substance through the nose in an amount that is insufficient to stimulate an excretory response that would clear a significant portion of the substance from nasal and sinus passages is repeated. The repeated application, at a minimum, is done a sufficient number of times to provide an effective total dose of the substance. The repeated application, in any case, is done at least once.Type: ApplicationFiled: November 5, 2001Publication date: December 26, 2002Inventors: Yasmin Thanavala, Anju Visweswaraiah, Lauren O. Bakaletz, Laura Anne Novotny
-
Publication number: 20020004076Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to the NEPA may be boosted in the animal by feeding the animal the plant material containing the NEPA. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g.Type: ApplicationFiled: December 16, 1999Publication date: January 10, 2002Inventor: YASMIN THANAVALA
-
Patent number: 5856087Abstract: The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permited variants thereof, which, like 2F10, have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10.Type: GrantFiled: October 10, 1997Date of Patent: January 5, 1999Assignees: Health Research, Inc., University College LondonInventors: Yasmin Thanavala, Arvind Thakur
-
Patent number: 5744135Abstract: The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permitted variants thereof, which, like 2F10, have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10.Type: GrantFiled: January 19, 1996Date of Patent: April 28, 1998Assignees: Health Research, Inc., University College LondonInventors: Yasmin Thanavala, Arvind Thakur, Ivan Roitt, Michael Pride
-
Patent number: 5668253Abstract: The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permited variants thereof, which, like 2F10, have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10.Type: GrantFiled: April 5, 1995Date of Patent: September 16, 1997Assignees: Health Research, Inc., University College LondonInventors: Yasmin Thanavala, Arvind Thakur, Ivan Roitt, Michael Pride
-
Patent number: 5531990Abstract: The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not complete homology with such surface antigen. The invention further comprises a peptide having a chain comprising the amino acid residues Ala Val Tyr Tyr Cys Thr Arg Gly Tyr His Gly Ser Ser Leu Tyr and permited variants thereof, which, like 2F10, have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial, but not complete, homology with said surface antigen. The amino acid sequence is found in and forms a part of 2F10.Type: GrantFiled: December 15, 1993Date of Patent: July 2, 1996Assignees: Health Research, Inc., University College LondonInventors: Yasmin Thanavala, Arvind Thakur, Ivan Roitt, Michael Pride